Readmission in patients undergoing percutaneous patent foramen ovale closure in the United States. (1st January 2023)

• Record Type: Journal Article
• Authors: Krittanawong, Chayakrit; Yue, Bing; Khawaja, Muzamil; Kumar, Anirudh; Virk, Hafeez Ul Hassan; Wang, Zhen; Hanif, Sana; Khalid, Umair; Denktas, Ali E.; Kavinsky, Clifford J.; Volpi, John J.; Jneid, Hani
• Is Part Of: International journal of cardiology. Volume 370(2023)
• Page Start: 143
• Page End: 148
• Publication Date: 2023-01-01
• Subjects: Patent foramen ovale -- Nationwide readmissions database; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2022.10.135
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Current estimates suggest that a patent foramen ovale (PFO) may exist in up to 25% of the general population and is a potential risk factor for embolic, ischemic stroke. PFO closure complications include bleeding, need for procedure-related surgical intervention, pulmonary emboli, device malpositioning, new onset atrial arrhythmias, and transient atrioventricular block. Rates of PFO closure complications at a national level in the Unites States remain unknown. To address this, we performed a contemporary nationwide study using the 2016 and 2017 Nationwide Readmissions Database (NRD) to identify patterns of readmissions after percutaneous PFO closure. In conclusion, our study showed that following PFO closure, the most common complications were atrial fibrillation/atrial flutter followed by acute heart failure syndrome, supraventricular tachycardia and acute myocardial infarction. Highlights: The most common reason for readmission following PFO closure was postprocedural complications Following PFO closure, the most common complications were atrial fibrillation/flutter, heart failure, supraventricular tachycardia and acute myocardial infarction. ESRD and median quartile household income had a significant association with 30-day readmission Our study is purely observational and any significant associations seen cannot be identified as causal until future randomized clinical trials are undertaken